Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.
Q3 FY26 Earnings Results
- Revenue from Operations: ₹3,567 cr, +11.5% YoY (vs ₹3,200+ cr last year) driven by strong domestic chronic portfolio demand.
- EBITDA: ₹925 cr implied at 25.9% EBITDA margin expanded margins demonstrate operating leverage.
- PAT: ₹410 cr, +7.7% YoY on improved demand and margin mix.
- EPS: ₹9.9.
- Segments/Geography: Domestic market share in chronic drugs improved to 39.3%; exports also grew in double-digits supporting topline.
Management Commentary & Strategic Decisions
- Management highlighted robust demand for chronic therapy drugs (cardiac and anti-diabetes), seen as the major revenue driver in Q3, suggesting sustained strength in high-growth therapeutic areas.
- EBITDA margin enhancement was attributed to cost efficiencies and improved mix focusing on higher-margin chronic and specialty products.
- Strategic initiatives around BSV integration and specialty portfolio expansion continue to support pipeline and future growth momentum.
Q2 FY26 Earnings Results
- Revenue from Operations: ₹3,697 cr, +20.8% YoY, strong year-on-year growth driven by chronic segment and BSV business consolidation.
- EBITDA: ₹924 cr, 25% margin, reflecting solid profitability with scale.
- PAT: ₹520 cr, -21% YoY (vs ₹661 cr in Q2 FY25), impacted by higher expenses and segment mix.
- EPS: ₹12.4 (diluted EPS).
Management Commentary Q2
- Vice Chairman & MD Rajeev Juneja attributed Q2 growth to outperformance in chronic therapies and BSV integration, though he acknowledged OTC segment pressure due to GST transition and weather impacts.
- Management reaffirmed confidence in long-term growth driven by four pillars: steady base business, specialty chronic portfolio, high-potential OTC, and BSV super-specialty offerings.
- Margin resilience and revenue diversification (domestic + exports) were highlighted as key strengths going forward.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.